Trials / Completed
CompletedNCT02561000
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Tufts Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac events such as heart attack, bypass surgery or stroke compared with those persons treated with the standard of care.
Conditions
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Coronary Disease
- Arteriosclerosis
- Heart Diseases
- Myocardial Ischemia
- Vascular Diseases
- Acute Coronary Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PZ-128 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-05-27
- Primary completion
- 2019-09-17
- Completion
- 2019-09-17
- First posted
- 2015-09-25
- Last updated
- 2025-04-16
- Results posted
- 2021-03-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02561000. Inclusion in this directory is not an endorsement.